Episode 193: Intensive BP lowering, elinzanetant for VMS, HTN in pregnancy and prostate CA screening

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/ff/fa/bb/fffabb25-8701-3ec5-10a1-d7360cf6f757/mza_7800572450694007186.jpg/600x600bb.jpg

Primary Care Update

Mark Ebell

193 episodes

6 days ago

Four healthily skeptical primary care physicians discuss the latest in primary care medicine. Join Essential Evidence Editor Mark Ebell MD, Rush University's Kate Rowland MD, MSU Professor of Medicine Gary Ferenchick MD, and POEMs co-founder Henry Barry MD, MS for this fast-paced weekly update on evidence-based primary care.

Medicine

Health & Fitness

RSS

All content for Primary Care Update is the property of Mark Ebell and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/807823/807823-1535146710716-0fbae5650ccb6.jpg

Episode 193: Intensive BP lowering, elinzanetant for VMS, HTN in pregnancy and prostate CA screening

Primary Care Update

38 minutes 12 seconds

6 days ago

Episode 193: Intensive BP lowering, elinzanetant for VMS, HTN in pregnancy and prostate CA screening

Primary care physicians Gary Ferenchick, Kate Rowland, Henry Barry and Mark Ebell want you to know about 4 new studies: the best choice of pharmacotherapy in hypertensive disorders of pregnancy, benefits and harms of intensive BP lowering, elinzanetant for therapy-induced vasomotor symptoms in women with breast cancer, and 23 year follow up of the European Prostate Cancer Screening Trial. Plus a confusing quiz question (thanks Gary!).

Links

Essential Evidence Plus: www.essentialevidenceplus.com

HTN in pregnancy: https://pubmed.ncbi.nlm.nih.gov/40216176/

Intensive BP lowering: https://pubmed.ncbi.nlm.nih.gov/40902616/

Elinzanetant for vasomotor symptoms in patients taking tamoxifen or anastrozole: https://pubmed.ncbi.nlm.nih.gov/40454634/

23 year follow-up of large European prostate cancer study: https://pubmed.ncbi.nlm.nih.gov/41160819/